Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Supplier-published stability data is the appropriate reference
(NYSE: PFE) is the world's second-largest pharmaceutical company by 2024 revenue at USD 63.6 billion, but its ranking at #7 in the peptide therapy context reflects the company's limited direct exposure to the GLP-1/GIP revolution that defines the market's highest-growth segment
J., Dansen, T
Cardiovascular safety monitoring was standard per protocolno signals beyond expected GLP-1 class effects
US$ 24.23
US$ 20.82
US$ 22.03
US$ 22.25
US$ 20.97
